Pharmacy Times July 29, 2024
The blood test offers patients advanced screening methods capable of detecting colorectal cancer in its earlier stages.
A novel blood test (Shield; Guardant Health, Inc) for colorectal cancer (CRC) screening received FDA approval for adults ages 45 and older who are at average risk of the disease. The decision is based on positive results from the ECLIPSE trial (NCT04136002), which showed that the blood test demonstrated 83% sensitivity for the detection of CRC. The test paves the way for less invasive, efficacious diagnostic treatments that improve screening rates to help clinicians and patients detect CRC in its earlier stages.1
According to the American Cancer Society, there will be approximately 106,590 new cases of colon cancer (54,210 in men and 52,380...
Today's Sponsors
Today's Sponsor